Osteoporosis is the chronic condition of bone associated with decreased bone density, quality of bones and increased risks of fractures. Postmenopausal osteoporosis deals with increased bone resorption that results in loss of bone and fragility over 45 years of women. One of the leading causes of postmenopausal osteoporosis is the reduction of estrogen production in the ovaries of females. Lack of estrogen triggers several bone turnover pathways that result in osteoporosis. The drop of estrogen in the postmenopausal transition period, causes more bone resorption as compared to bone formation resulting in postmenopausal osteoporosis. Osteoporotic fractures is the major threat to the health of the women due to postmenopausal osteoporosis and hormone therapy is considered the first line therapy against this disease. To date, several pharmacological and non-pharmacological approaches have been designed to treat postmenopausal osteoporosis. Bone turnover markers help in the monitoring of osteoporosis treatment and in the assessment of fracture risk. Besides these conventional therapies, novel and advanced strategies have been constructed for the treatment of osteoporosis. Probiotics Choice and Ovarian Follicular Pool have opened a new avenue to treat osteoporosis. This review shed light on the biochemical perspective of postmenopausal osteoporosis, novel methods for its treatment, and management therapies to treat postmenopausal osteoporosis.
| Published in | American Journal of Nursing and Health Sciences (Volume 2, Issue 2) |
| DOI | 10.11648/j.ajnhs.20210202.12 |
| Page(s) | 33-38 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Postmenopausal Osteoporosis, Estrogen, Bone Turnover Markers, Probiotics, Ovarian Follicular Pool
| [1] | Li, X., et al., Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 2009. 24 (4): p. 578-588. |
| [2] | Brandão, C. M. R., et al., Treatment of postmenopausal osteoporosis in women: a systematic review. Cadernos de saude publica, 2008. 24: p. s592-s606. |
| [3] | MacLean, C., et al., Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of internal medicine, 2008. 148 (3): p. 197-213. |
| [4] | Andersen, C. Y. and S. G. Kristensen, Novel use of the ovarian follicular pool to postpone menopause and delay osteoporosis. Reproductive biomedicine online, 2015. 31 (2): p. 128-131. |
| [5] | Briot, K., et al., 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine, 2012. 79 (3): p. 304-313. |
| [6] | Khosla, S., L. J. Melton, and B. L. Riggs, The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? Journal of Bone and Mineral Research, 2011. 26 (3): p. 441-451. |
| [7] | Mödder, U. I., Clowes, J. A., Hoey, K., Peterson, J. M., McCready, L., Oursler, M. J., & Khosla, S. (2011). Regulation of circulating sclerostin levels by sex steroids in women and in men. Journal of Bone and Mineral Research, 26 (1), 27-34. |
| [8] | Fraser, W. D., Hyperparathyroidism. The Lancet, 2009. 374 (9684): p. 145-158. |
| [9] | Ellegaard, M., Jørgensen, N. R., & Schwarz, P. (2010). Parathyroid hormone and bone healing. Calcified tissue international, 87 (1), 1-13. Lerner, U., Bone remodeling in post-menopausal osteoporosis. Journal of dental research, 2016. |
| [10] | Vasikaran, S., et al., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011. 22 (2): p. 391-420. |
| [11] | Thomas, C. and S. Devika, Bone turnover markers. Australian Prescriber, 2012. 35 (5). |
| [12] | Yap, C. Y. and T. C. Aw, Bone turnover markers. Proceedings of Singapore Healthcare, 2010. 19 (3): p. 273-275. |
| [13] | Koivula, M.-K., et al., Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clinical biochemistry, 2010. 43 (18): p. 1453-1457. |
| [14] | Brown, J. P., et al., Bone turnover markers in the management of postmenopausal osteoporosis. Clinical biochemistry, 2009. 42 (10-11): p. 929-942. |
| [15] | Yousf, H., G. Tomar, and R. Kr Srivastava, Probiotics and Bone Health: It takes GUTS to improve bone density. Int J Immunother Cancer Res 1 (1): 018, 2015. 22. |
| [16] | Qin, J., et al., A human gut microbial gene catalogue established by metagenomic sequencing. nature, 2010. 464 (7285): p. 59. |
| [17] | Parvaneh, K., et al., Effect of probiotics supplementation on bone mineral content and bone mass density. The Scientific World Journal, 2014. 2014. |
| [18] | Maynard, C. L., et al., Reciprocal interactions of the intestinal microbiota and immune system. Nature, 2012. 489 (7415): p. 231. |
| [19] | Tremaroli, V. and F. Bäckhed, Functional interactions between the gut microbiota and host metabolism. Nature, 2012. 489 (7415): p. 242. |
| [20] | Sjögren, K., et al., The gut microbiota regulates bone mass in mice. Journal of Bone and Mineral Research, 2012. 27 (6): p. 1357-1367. |
| [21] | Cho, I., et al., Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature, 2012. 488 (7413): p. 621. |
| [22] | Bron, P. A., P. Van Baarlen, and M. Kleerebezem, Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nature Reviews Microbiology, 2012. 10 (1): p. 66. |
| [23] | Ohlsson, C., et al., Probiotics protect mice from ovariectomy-induced cortical bone loss. PloS one, 2014. 9 (3): p. e92368. |
| [24] | Lavasani, S., et al., A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PloS one, 2010. 5 (2): p. e9009. |
| [25] | Consensus, N., Development panel on osteoporosis: prevention, diagnosis and therapy. Jama, 2001. 285 (6): p. 785-795. |
| [26] | Cosman, F., et al., Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis international, 2014. 25 (10): p. 2359-2381. |
| [27] | Health, N. I. o., Osteoporosis prevention, diagnosis, and therapy. NIH consensus statement, 2000. 17 (1): p. 1-36. |
| [28] | Åkesson, K., New approaches to pharmacological treatment of osteoporosis. Bulletin of the World Health Organization, 2003. 81 (9): p. 657-663. |
| [29] | Kanis, J. A., et al., European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis international, 2013. 24 (1): p. 23-57. |
| [30] | Health, U. D. o. and H. Services, Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004. 87. |
| [31] | Andreopoulou, P. and R. S. Bockman, Management of postmenopausal osteoporosis. Annual review of medicine, 2015. 66: p. 329-342. |
| [32] | Bernabei, R., et al., Screening, diagnosis and treatment of osteoporosis: a brief review. Clinical Cases in Mineral and Bone Metabolism, 2014. 11 (3): p. 201. |
| [33] | Tella, S. H. and J. C. Gallagher, Prevention and treatment of postmenopausal osteoporosis. The Journal of steroid biochemistry and molecular biology, 2014. 142: p. 155-170. |
| [34] | Reid, I. R., M. J. Bolland, and A. Grey, Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. The Lancet, 2014. 383 (9912): p. 146-155. |
APA Style
Nabiha Khalid, Quratulain Yousaf, Lubna Shehzadi, Sehrish Fatima. (2021). Postmenopausal Osteoporosis: A Primary Women Health Concern. American Journal of Nursing and Health Sciences, 2(2), 33-38. https://doi.org/10.11648/j.ajnhs.20210202.12
ACS Style
Nabiha Khalid; Quratulain Yousaf; Lubna Shehzadi; Sehrish Fatima. Postmenopausal Osteoporosis: A Primary Women Health Concern. Am. J. Nurs. Health Sci. 2021, 2(2), 33-38. doi: 10.11648/j.ajnhs.20210202.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajnhs.20210202.12,
author = {Nabiha Khalid and Quratulain Yousaf and Lubna Shehzadi and Sehrish Fatima},
title = {Postmenopausal Osteoporosis: A Primary Women Health Concern},
journal = {American Journal of Nursing and Health Sciences},
volume = {2},
number = {2},
pages = {33-38},
doi = {10.11648/j.ajnhs.20210202.12},
url = {https://doi.org/10.11648/j.ajnhs.20210202.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajnhs.20210202.12},
abstract = {Osteoporosis is the chronic condition of bone associated with decreased bone density, quality of bones and increased risks of fractures. Postmenopausal osteoporosis deals with increased bone resorption that results in loss of bone and fragility over 45 years of women. One of the leading causes of postmenopausal osteoporosis is the reduction of estrogen production in the ovaries of females. Lack of estrogen triggers several bone turnover pathways that result in osteoporosis. The drop of estrogen in the postmenopausal transition period, causes more bone resorption as compared to bone formation resulting in postmenopausal osteoporosis. Osteoporotic fractures is the major threat to the health of the women due to postmenopausal osteoporosis and hormone therapy is considered the first line therapy against this disease. To date, several pharmacological and non-pharmacological approaches have been designed to treat postmenopausal osteoporosis. Bone turnover markers help in the monitoring of osteoporosis treatment and in the assessment of fracture risk. Besides these conventional therapies, novel and advanced strategies have been constructed for the treatment of osteoporosis. Probiotics Choice and Ovarian Follicular Pool have opened a new avenue to treat osteoporosis. This review shed light on the biochemical perspective of postmenopausal osteoporosis, novel methods for its treatment, and management therapies to treat postmenopausal osteoporosis.},
year = {2021}
}
TY - JOUR T1 - Postmenopausal Osteoporosis: A Primary Women Health Concern AU - Nabiha Khalid AU - Quratulain Yousaf AU - Lubna Shehzadi AU - Sehrish Fatima Y1 - 2021/04/20 PY - 2021 N1 - https://doi.org/10.11648/j.ajnhs.20210202.12 DO - 10.11648/j.ajnhs.20210202.12 T2 - American Journal of Nursing and Health Sciences JF - American Journal of Nursing and Health Sciences JO - American Journal of Nursing and Health Sciences SP - 33 EP - 38 PB - Science Publishing Group SN - 2994-7227 UR - https://doi.org/10.11648/j.ajnhs.20210202.12 AB - Osteoporosis is the chronic condition of bone associated with decreased bone density, quality of bones and increased risks of fractures. Postmenopausal osteoporosis deals with increased bone resorption that results in loss of bone and fragility over 45 years of women. One of the leading causes of postmenopausal osteoporosis is the reduction of estrogen production in the ovaries of females. Lack of estrogen triggers several bone turnover pathways that result in osteoporosis. The drop of estrogen in the postmenopausal transition period, causes more bone resorption as compared to bone formation resulting in postmenopausal osteoporosis. Osteoporotic fractures is the major threat to the health of the women due to postmenopausal osteoporosis and hormone therapy is considered the first line therapy against this disease. To date, several pharmacological and non-pharmacological approaches have been designed to treat postmenopausal osteoporosis. Bone turnover markers help in the monitoring of osteoporosis treatment and in the assessment of fracture risk. Besides these conventional therapies, novel and advanced strategies have been constructed for the treatment of osteoporosis. Probiotics Choice and Ovarian Follicular Pool have opened a new avenue to treat osteoporosis. This review shed light on the biochemical perspective of postmenopausal osteoporosis, novel methods for its treatment, and management therapies to treat postmenopausal osteoporosis. VL - 2 IS - 2 ER -
Information
Email: